entertainment -WSS

entertainment

author：focus 2025-10-01 17:35:25 - browse：26

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Health insurers' Q3 question: how much care are people getting?

hotspot

WSS

With Roe v Wade overturned, abortion providers work to adapt

RSV injection headlines need to be accurate for good uptake

6 solutions to address cancer drug shortages and others

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

6 solutions to address cancer drug shortages and others

leisure time

entertainment

knowledge

In age of alternative facts, a scholarly course on calling out crap

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Alkermes shareholders re

Surge of respiratory disease in China has likely explanation

After affirmative action ruling, medical educators look to 'holistic review'

Nobel honors Karikó and Weissman's enduring partnership

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Trump demands the U.S. pay no more for drugs than other countries … again

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

Congress extends some pandemic preparedness programs

Some top drug companies are starting to take action on climate

Health insurers' Q3 question: how much care are people getting?

Medicare innovation center doesn’t save money, experts say

Gain of function research would be limited under House proposal

European officials brace for rough respiratory virus season

hotspot

explore

knowledge

hotspot